Skip to main content
Equibles

PROCF · Sofgen Pharma S.A.

Track PROCF — free

Use PROCF with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PROCF.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.03 +0.00 (+0.00%) At close · Oct 15
Rebalance outlook locked
Market Cap
$58.18M
Shares
2.33B
Volume · Oct 15 314.27K Avg daily vol (8 sessions) 39.94K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.03 Open$0.03 Day$0.03–0.03 Available close range$0.00–0.15 Avg vol 30d12K Short int28K · 0.0% float · 999+d Short vol100% DataOct 2021–Oct 2026

The closing range uses available history since Nov 3, 2025; less than a full year is stored.

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
-2.1%
Year over year
Operating margin
-14.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.0%
Year over year
Price change (1Y)
-98.2%
Trailing year
Short interest
0.0%
Latest settlement · 999+ days to cover
View all 122 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 18.4 · elevated Equity put/call 0.55
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −98%
below
Price vs 50-day avg −95%
below
RSI (14) 37
neutral
MACD trend Positive
52-week position 17%
mid-range
Momentum
relative strength
Weak
1-month return +2173%
trailing
6-month return −99%
trailing
YTD return 0%
this year
Relative strength −107%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow Flat
0% holders QoQ · +2 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
0.00% of float · ▬ 0.0% MoM · 1000.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
6 holders — near 3-yr low, contrarian setup
Squeeze score 39
low risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 28292%
annualized · 1-yr
Max drawdown −100%
past year
ATR 220.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−98% Bearish
Price vs 50-day avg
−95% Bearish
RSI (14)
37 Neutral
MACD trend
Positive Bullish
52-week position
17% Neutral
Market signals — smart money & positioning
No clear signal
Trend (MA cross) No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow Flat
0% holders QoQ · +2 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
0.00% of float · ▬ 0.0% MoM · 1000.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
6 holders — near 3-yr low, contrarian setup
Price context
position in its available closing range
Range low $0 Now $0 · 17% Range high $0
vs 200-day avg -98% vs 50-day avg -95%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
PROCF
Sofgen Pharma S.A.
this stock
$58.18M -0.4% — — 0.0%
TAK
Takeda Pharmaceutical Co Ltd
 $62.65B +28.8% — — 0.1%
GALDY
Galderma Group AG/ADR
 $48.90B +1.1% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
 $48.14B +30.9% +4.3% 67.7 2.6%
HLN
Haleon plc
 $44.59B +0.6% — — 0.6%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
6
% held
0.0%
Net QoQ
+55.3K sh
Top holder
Itau Unibanco Holding S.A.
Held Float
View
Short & Settlement
Short Interest
Shares short
27.6K
Days to cover
1000.0d
Change
0 sh
View
Short Volume
Short vol %
100%
As of
Aug 12, 2026
Short Total
View
Fails to Deliver
FTD shares
250
Value
$3
As of
Oct 22, 2025
View
Off-Exchange
Off-exchange %
100.0%
Week of
Sep 14, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
20-F
Filed
Mar 16, 2026
This year
1
View

Performance

5D 20D 120D MTD YTD
PROCF +98.4% +2172.7% -99.3% +24900.0% -0.4%
SPY -0.3% +1.2% +8.1% +1.2% +13.2%
vs SPY +98.7% +2171.5% -107.4% +24898.8% -13.6%
Key facts CIK 1863362 Visit website Investor relations